Loading...
Market
Story
Lenacapavir Named 'Discovery of the Year' by Science for 100% Efficacy in 2024 HIV Clinical Trial
Dec 13, 2024, 11:51 AM
A new injectable medication, lenacapavir, has been recognized as the 'discovery of the year' by the journal Science for its ability to prevent HIV infection. The medication demonstrated 100% efficacy in a clinical trial involving women in Africa. Global leaders are rallying behind this breakthrough, emphasizing its potential to eliminate HIV worldwide. The recognition of lenacapavir highlights significant advancements in the fight against the virus, marking a pivotal moment in medical research and public health efforts.
View original story
Similar markets
Dr. Reddy's Laboratories • 25%
Cipla • 25%
Mylan • 25%
Other • 25%
Pfizer • 25%
Merck • 25%
Johnson & Johnson • 25%
Other • 25%
Government • 33%
Non-Governmental Organization (NGO) • 33%
Private Sector • 34%
India • 25%
South Africa • 25%
Brazil • 25%
Other • 25%
Global Fund • 25%
PEPFAR • 25%
Gilead Sciences • 25%
Other • 25%
United States • 25%
European Union • 25%
South Africa • 25%
Other • 25%
North America • 25%
Europe • 25%
Africa • 25%
Asia • 25%
India • 25%
South Africa • 25%
Brazil • 25%
Other • 25%
0-10 • 25%
11-30 • 25%
31-60 • 25%
61+ • 25%
Approved in USA only • 25%
Approved in EU only • 25%
Approved in both USA and EU • 25%
Not approved in USA or EU • 25%
0 • 25%
1 • 25%
2 • 25%
3 or more • 25%